Below you'll find a list of all posts from September, 2022
The FDA’s decision to approve Amylyx Pharmaceuticals’ therapeutic compound AMX0035 for treatment of ALS was fully justified by the data and the science. Clinicians, researchers, advocacy groups, and people living with ALS spoke in overwhelming numbers in favor of approval. …
As a healthcare worker, Tina cared for people diagnosed with ALS, including her mother. Prior to her mom’s passing in 2018, Tina started to experience symptoms that were eerily familiar. “Towards the end of my mother’s battle with ALS, I began …
New results published this week provide further evidence that tofersen, a drug in development by Biogen, may be effective in slowing the progression of SOD1-ALS. As reported in the New England Journal of Medicine, the Phase 3 clinical trial (VALOR) …
Foundation News These people are unstoppable. The ALS Walk for Life brings together thousands of walkers who have dedicated their time to helping people living with ALS. We’re excited to gather with the ALS community and raise much needed …
Foundation News ALS Walk for Life, Saturday, September 24! If this is your first ALS Walk for Life, you’re not alone. Suzanne will be participating in the Walk for the first time – and walking in memory of her …
Watch our oral testimony at the FDA Advisory Committee meeting on September 7, 2022. We are grateful to the FDA Advisory Committee for examining the evidence, listening to the ALS community, and voting to recommend approval of Amylyx Pharmaceuticals’ therapeutic …
Delivered by Andrea Pauls Backman, CEO of the Les Turner ALS Foundation. Slides can be seen here (PDF). Open Public Hearing FDA Advisory Committee on AMX0035 September 7, 2022 Good afternoon. My name is Andrea Pauls Backman, CEO of the …
The Centers for Medicare & Medicaid Services have opened a comment period on Medicare coverage of power seat elevation systems in power wheelchairs. The Les Turner ALS Foundation strongly supports power seat elevation coverage and has submitted the comments below. …
